{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Alpha Cognition Inc."},"Symbol":{"label":"Symbol","value":"ACOG"},"Address":{"label":"Address","value":"1200-750 W PENDER ST, VANCOUVER, British Columbia, V6C 2T8, Canada"},"Phone":{"label":"Phone","value":"(858) 344-4375"},"Industry":{"label":"Industry","value":null},"Sector":{"label":"Sector","value":null},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The Company's pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company's ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for traumatic brain injury. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein."},"CompanyUrl":{"label":"Company Url","value":"alphacognition.com"},"KeyExecutives":{"label":"Key Executives","value":[]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}